Home

Specific anti-cancer vaccines in vivo.

Modiblast Pharma, a startup ready to enter the clinical phase with novel Dendritic Cell Therapies for liquid cancers, targets the core issue in acute myeloid leukemias (AML): the extremely high rate of relapses after successful initial therapy.  Our novel approach uses a combination of endogenous substances to induce blast cells in the patient to differentiate into leukemia-specific dendritic cells (DC_leu), which in turn trigger both innate and adaptive immune cells in blood/tissue to kill remaining/recurring blasts and generate memory cells.

The combination of immunomodulators induces a patient-specific therapeutic vaccine in vivo. Thus, the individual repertoire of leukemic anti­gens of this patient can be presented, circumventing the need to identify and select specific target molecules. This approach entails a huge advantage: it doesn’t require complicated/expensive ex vivo procedures or GMP facilities.

Our long-term goal is to provide an easy-to-use self-administered drug that can stabilize remissions or halt progression of the disease. This therapy is also intended for patients with myelodysplastic syndrome and may normalize thrombocyte/neutrophil counts.